NasdaqGM - Delayed Quote • USD
Revance Therapeutics, Inc. (RVNC)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 5 |
| Avg. Estimate | -0.75 | -0.51 | -2.3 | -1.06 |
| Low Estimate | -1.19 | -0.56 | -3.24 | -1.22 |
| High Estimate | -0.5 | -0.46 | -1.61 | -0.78 |
| Year Ago EPS | -0.74 | -0.8 | -3.83 | -2.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 10 | 10 |
| Avg. Estimate | 56.63M | 68.21M | 281.72M | 382.52M |
| Low Estimate | 53.47M | 64M | 272.88M | 341M |
| High Estimate | 59.6M | 72.83M | 288M | 406.96M |
| Year Ago Sales | 49.33M | 58.13M | 234.04M | 281.72M |
| Sales Growth (year/est) | 14.80% | 17.30% | 20.40% | 35.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.7 | -0.78 | -0.85 | -0.72 |
| EPS Actual | -0.74 | -0.8 | -1.63 | -0.62 |
| Difference | -0.04 | -0.02 | -0.78 | 0.1 |
| Surprise % | -5.70% | -2.60% | -91.80% | 13.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.75 | -0.51 | -2.3 | -1.06 |
| 7 Days Ago | -0.75 | -0.51 | -2.3 | -1.06 |
| 30 Days Ago | -0.75 | -0.51 | -2.3 | -1.06 |
| 60 Days Ago | -0.61 | -0.47 | -1.9 | -0.91 |
| 90 Days Ago | -0.59 | -0.44 | -1.79 | -0.69 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | RVNC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -1.40% | -- | -- | 2.60% |
| Next Qtr. | 36.30% | -- | -- | 13.40% |
| Current Year | 39.90% | -- | -- | 5.20% |
| Next Year | 53.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 11.60% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 3/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/29/2024 |
| Maintains | Needham: Buy to Buy | 2/29/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/23/2024 |
| Maintains | Barclays: Overweight to Overweight | 1/29/2024 |
Related Tickers
AMLX Amylyx Pharmaceuticals, Inc.
1.7800
-5.32%
OCUL Ocular Therapeutix, Inc.
4.2000
-9.58%
ARQT Arcutis Biotherapeutics, Inc.
8.59
-1.83%
SAGE Sage Therapeutics, Inc.
13.58
-3.00%
KPTI Karyopharm Therapeutics Inc.
1.0600
-2.75%
CHRS Coherus BioSciences, Inc.
1.9300
-4.46%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
ADCT ADC Therapeutics SA
4.4400
-7.11%
MRSN Mersana Therapeutics, Inc.
2.8500
-1.04%
SLRN Acelyrin, Inc.
4.2400
-7.22%